Tactile Systems Technology Inc (TCMD) Stock Analysis and Metrics

Tactile Systems Technology

NASDAQ: TCMD

$27.48 ▲ +0.04 (+0.15%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap619.08 Mn

P/E30.59

P/S1.80

Div. Yield0.00

Revenue Growth (1y) (Qtr)22.85

Add ratio to table…

About

Tactile Systems Technology, Inc. is a medical technology company that develops and provides innovative medical devices for the treatment of underserved chronic diseases. The company focuses on vascular disease, oncology related lymphedema, and airway clearance therapy for chronic respiratory conditions. Its core products include pneumatic compression systems for lymphedema and a wearable high frequency chest oscillation vest for respiratory care. Tactile Systems Technology, Inc. delivers these solutions primarily to patients in the United States through a combination of direct to patient and distributor channels.

The company generates revenue by selling and renting its lymphedema therapy systems and its airway clearance vest. In 2025 total revenue reached $329.5 million, of which $278.4 million (84%) came from lymphedema products such as the Flexitouch Plus, Entre Plus and Nimbl systems, and $51.1 million (16%) came from the AffloVest airway clearance system. Lymphedema revenue is derived mainly from a direct to patient model where the company obtains clinician referrals, manages insurance claims, ships devices to patients and provides training. Airway clearance revenue follows a durable medical equipment distribution model in which the company sells AffloVest to accredited DME providers who then handle reimbursement, patient training and ongoing support.

The company operates through the following segments:

• Lymphedema Therapies: This segment includes the design, manufacture and sale of pneumatic compression devices such as Flexitouch Plus, Entre Plus and Nimbl, which are used for at home treatment of lymphedema, chronic venous insufficiency and related conditions.

• Airway Clearance Therapies: This segment comprises the AffloVest wearable vest that delivers high frequency chest wall oscillation to mobilize lung secretions for patients with bronchiectasis, cystic fibrosis and other chronic respiratory disorders.

Within the medical device industry, Tactile Systems Technology, Inc. holds a differentiated position by combining proprietary technology with a direct to patient commercial model that captures both manufacturer and distributor margins. Its main competitors in the pneumatic compression space include Bio Compression Systems, Inc. and Lympha Press USA, while in the airway clearance market it faces Baxter (formerly Hill Rom), Philips Medical and Electromed. The company’s competitive advantages stem from its extensive reimbursement infrastructure, strong clinical evidence base, patented garment technology and a large network of account managers and specialists that support physician and patient education.

The company serves patients suffering from lymphedema, chronic venous insufficiency, oncology related lymphedema and chronic respiratory conditions such as bronchiectasis. In 2025 it treated over 84,000 patients with its compression therapy devices and has cumulatively served more than 635,000 patients since product launch. For its airway clearance business it works with durable medical equipment providers who prescribe and support the AffloVest for individuals with respiratory disorders. No specific customer names are disclosed in the filing.

Investment Thesis

▲ Bull case

The company’s strategic acquisition of Lymphotech brings a FDA cleared 3D measurement and monitoring platform that addresses a critical gap in the lymphedema care continuum. Management highlighted that Lymphotech’s technology replaces time consuming manual methods and is already generating revenue through newly awarded federal research grants under the LIGHT and GUIDE programs. These grants not only provide non dilutive funding but also validate the clinical relevance of the diagnostic solution, creating a pathway for future reimbursement through CPT code approval. The integration of Lymphotech’s data capabilities with existing therapy products positions the firm to offer an end to end solution that can improve patient outcomes and increase lifetime value, a catalyst that is not yet reflected in current guidance but could drive multiple expansion as adoption scales.
The upcoming launch of the next generation AffloVest device represents a meaningful product refresh that enhances patient experience through weight reduction digital connectivity and improved adjustability while retaining the same reimbursement structure as the legacy model. Although no incremental reimbursement is attached to the new features the company expects the improved usability to drive higher penetration within its existing DME network and accelerate adoption among underserved bronchiectasis patients. Management noted that the device is on track for commercial availability in time for the 2026 to 2027 winter respiratory season and that the launch is already incorporated into the full year growth outlook. This product led upside could accelerate airway clearance revenue growth beyond the modest pace assumed in guidance especially if DME partners prioritize the newer model during seasonal demand peaks.
Artificial intelligence enabled back office transformation is delivering tangible efficiency gains that should support margin expansion over the medium term. The firm accelerated the prior authorization module of its AI platform ahead of the April 2026 Medicare fee for service go live date demonstrating operational agility and reducing the risk of claim denials. Management indicated that future AI enhancements will extend to patient eligibility benefits verification and full medical record review which could lower administrative costs and improve speed of therapy. These process improvements are described as structural rather than temporary cost actions suggesting a sustainable pathway to higher adjusted EBITDA margins as the technology scales across the order workflow.
Underlying demand for both lymphedema and airway clearance therapies remains durable as evidenced by broad based revenue growth across volume and revenue per unit in the first quarter. The company cited strong collections favorable payer mix and continued strength in commercial and VA channels as signs that the core business is not dependent on any single temporary tailwind. While the new Medicare prior authorization process introduced early variability management expressed confidence that the process will normalize and that the firm’s experience in other prior authorization environments positions it to navigate the transition successfully. This durability of demand combined with the firm’s strategic levers provides a foundation for sustained top line expansion that could exceed the current 9% to 12% year over year guidance range.

The company’s strategic acquisition of Lymphotech brings a FDA cleared 3D measurement and monitoring platform that addresses a critical gap in the lymphedema care continuum. Management highlighted that Lymphotech’s technology replaces time consuming manual methods and is already generating revenue through newly awarded federal research grants under the LIGHT and GUIDE programs. These grants not only provide non dilutive funding but also validate the clinical relevance of the diagnostic solution, creating a pathway for future reimbursement through CPT code approval. The integration of Lymphotech’s data capabilities with existing therapy products positions the firm to offer an end to end solution that can improve patient outcomes and increase lifetime value, a catalyst that is not yet reflected in current guidance but could drive multiple expansion as adoption scales.
The upcoming launch of the next generation AffloVest device represents a meaningful product refresh that enhances patient experience through weight reduction digital connectivity and improved adjustability while retaining the same reimbursement structure as the legacy model. Although no incremental reimbursement is attached to the new features the company expects the improved usability to drive higher penetration within its existing DME network and accelerate adoption among underserved bronchiectasis patients. Management noted that the device is on track for commercial availability in time for the 2026 to 2027 winter respiratory season and that the launch is already incorporated into the full year growth outlook. This product led upside could accelerate airway clearance revenue growth beyond the modest pace assumed in guidance especially if DME partners prioritize the newer model during seasonal demand peaks.
Artificial intelligence enabled back office transformation is delivering tangible efficiency gains that should support margin expansion over the medium term. The firm accelerated the prior authorization module of its AI platform ahead of the April 2026 Medicare fee for service go live date demonstrating operational agility and reducing the risk of claim denials. Management indicated that future AI enhancements will extend to patient eligibility benefits verification and full medical record review which could lower administrative costs and improve speed of therapy. These process improvements are described as structural rather than temporary cost actions suggesting a sustainable pathway to higher adjusted EBITDA margins as the technology scales across the order workflow.
Underlying demand for both lymphedema and airway clearance therapies remains durable as evidenced by broad based revenue growth across volume and revenue per unit in the first quarter. The company cited strong collections favorable payer mix and continued strength in commercial and VA channels as signs that the core business is not dependent on any single temporary tailwind. While the new Medicare prior authorization process introduced early variability management expressed confidence that the process will normalize and that the firm’s experience in other prior authorization environments positions it to navigate the transition successfully. This durability of demand combined with the firm’s strategic levers provides a foundation for sustained top line expansion that could exceed the current 9% to 12% year over year guidance range.

▼ Bear case

The early implementation of the new Medicare prior authorization requirement has introduced administrative variability that management acknowledged but downplayed as temporary. The Q&A revealed differing approval rates among Medicare Administrative Contractors and a need for ongoing dialogue to achieve uniformity. This variability could lead to delayed claim processing increased denial rates and higher administrative burden if the MACs do not align their interpretations quickly. Although the company has built internal tools to manage the process the reliance on external payer behavior introduces a risk that near quarterly ordering patterns may remain inconsistent potentially pressuring sequential growth expectations.
Lymphotech’s near term financial contribution is largely derived from non recurring federal grant revenue which management admitted will not materially impact earnings this year. The diagnostic component of Lymphotech still requires FDA clearance for expanded indications and the establishment of CPT codes that enable reimbursement a process that could take multiple years. Until these milestones are achieved the core therapeutic business may not benefit from the expected cross sell opportunities and the acquisition could prove to be a capital intensive integration effort with uncertain returns. Investors should be cautious about overestimating the immediate upside from Lymphotech and consider the execution risk associated with merging two distinct product development roadmaps.
Despite the launch of the next generation AffloVest the company emphasized that reimbursement remains unchanged meaning the new features do not generate additional pricing power. Growth from this product will depend solely on increased adoption driven by patient experience improvements which may be slower than anticipated if DME partners are hesitant to shift inventory or if reimbursement policies continue to favor lower cost alternatives. The lack of a reimbursement premium limits the potential margin upside from the device refresh and places the burden on sales and marketing efforts to drive uptake a challenge that could weigh on operating leverage if adoption lags.
Operating expense growth remains elevated as the firm continues to invest in sales and marketing IT infrastructure and R&D while integrating Lymphotech. Management noted that a portion of the increase in OpEx is tied to lower margin grant related work from Lymphotech and one time acquisition costs. This cost base expansion could offset the benefits of gross margin improvement and delay the realization of meaningful operating leverage. If the anticipated productivity gains from the commercial organization and AI enabled efficiencies do not materialize as expected the firm may struggle to achieve the adjusted EBITDA target range of 49 million to 51 million for 2026 leaving profitability vulnerable to any further top line softness.

The early implementation of the new Medicare prior authorization requirement has introduced administrative variability that management acknowledged but downplayed as temporary. The Q&A revealed differing approval rates among Medicare Administrative Contractors and a need for ongoing dialogue to achieve uniformity. This variability could lead to delayed claim processing increased denial rates and higher administrative burden if the MACs do not align their interpretations quickly. Although the company has built internal tools to manage the process the reliance on external payer behavior introduces a risk that near quarterly ordering patterns may remain inconsistent potentially pressuring sequential growth expectations.
Lymphotech’s near term financial contribution is largely derived from non recurring federal grant revenue which management admitted will not materially impact earnings this year. The diagnostic component of Lymphotech still requires FDA clearance for expanded indications and the establishment of CPT codes that enable reimbursement a process that could take multiple years. Until these milestones are achieved the core therapeutic business may not benefit from the expected cross sell opportunities and the acquisition could prove to be a capital intensive integration effort with uncertain returns. Investors should be cautious about overestimating the immediate upside from Lymphotech and consider the execution risk associated with merging two distinct product development roadmaps.
Despite the launch of the next generation AffloVest the company emphasized that reimbursement remains unchanged meaning the new features do not generate additional pricing power. Growth from this product will depend solely on increased adoption driven by patient experience improvements which may be slower than anticipated if DME partners are hesitant to shift inventory or if reimbursement policies continue to favor lower cost alternatives. The lack of a reimbursement premium limits the potential margin upside from the device refresh and places the burden on sales and marketing efforts to drive uptake a challenge that could weigh on operating leverage if adoption lags.
Operating expense growth remains elevated as the firm continues to invest in sales and marketing IT infrastructure and R&D while integrating Lymphotech. Management noted that a portion of the increase in OpEx is tied to lower margin grant related work from Lymphotech and one time acquisition costs. This cost base expansion could offset the benefits of gross margin improvement and delay the realization of meaningful operating leverage. If the anticipated productivity gains from the commercial organization and AI enabled efficiencies do not materialize as expected the firm may struggle to achieve the adjusted EBITDA target range of 49 million to 51 million for 2026 leaving profitability vulnerable to any further top line softness.

Customer Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Products and Services Breakdown of Revenue (2025)

Customer Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Products and Services Breakdown of Revenue (2025)

Customer Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password